Bioavailability, Safety, and Tolerability of BIS-001 ER

Summary

This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring every 2-3 days until a maximum dose of 5mg per day is reached.

Timeline

Start

2017-05-22

Primary completion

2017-09-30

Completion

2017-09-30

Drugs

Indications